← Back to Search

Virus Therapy

CMV-MVA Triplex Vaccine for CMV Complications Post-Transplant

Phase 2
Waitlist Available
Led By Ryotaro Nakamura, MD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year post-hct

Summary

This trial is studying a vaccine that may help reduce CMV complications in patients who have had the virus before and are having a donor hematopoietic cell transplant.

Who is the study for?
This trial is for patients with certain blood cancers or disorders who've had CMV and are undergoing a donor bone marrow transplant. They must understand the study, agree to follow-up procedures for a year, be willing to use contraception, and not have received specific treatments that affect the immune system or CMV within the last 6 months.
What is being tested?
The trial tests if a vaccine made from weakened virus MVA carrying small pieces of CMV DNA can reduce complications from CMV in those getting bone marrow transplants. Participants will either get this experimental vaccine or a placebo to compare outcomes.
What are the potential side effects?
Potential side effects may include typical reactions at the injection site like pain and swelling, flu-like symptoms such as fever and fatigue, allergic reactions, and possibly others depending on how individuals respond to vaccines.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year post-hct
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year post-hct for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Cytomegalovirus (CMV) Events to Day 100
Incidence of Severe (Grade 3-4) Acute Graft-Versus-Host Disease
Secondary study objectives
All-cause Mortality

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm I (multi-peptide CMV-MVA vaccine)Experimental Treatment2 Interventions
Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
Group II: Arm II (placebo)Placebo Group2 Interventions
Patients receive placebo IM on days 28 and 56 post-HCT.

Find a Location

Who is running the clinical trial?

Diavax BiosciencesUNKNOWN
National Cancer Institute (NCI)NIH
13,927 Previous Clinical Trials
41,017,903 Total Patients Enrolled
7 Trials studying Lymphadenopathy
323 Patients Enrolled for Lymphadenopathy
City of Hope Medical CenterLead Sponsor
602 Previous Clinical Trials
1,923,478 Total Patients Enrolled
1 Trials studying Lymphadenopathy
3 Patients Enrolled for Lymphadenopathy

Media Library

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02506933 — Phase 2
Lymphadenopathy Research Study Groups: Arm I (multi-peptide CMV-MVA vaccine), Arm II (placebo)
Lymphadenopathy Clinical Trial 2023: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Highlights & Side Effects. Trial Name: NCT02506933 — Phase 2
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02506933 — Phase 2
~10 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top